Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

Lemée, Véronique; Leoz, Marie; Etienne, Manuel; Oliveira, Fabienne De; Plantier, Jean‐Christophe

doi:10.1128/jcm.01089-14

Cited by 8 publications

(8 citation statements)

References 16 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We prospectively recruited all patients from a TB research clinic who did not meet the inclusion criteria (at least one sputum sample positive for TB on Xpert) for the TB Sequel Project, a study exploring the impact of TB on lung function. 5 All patients underwent a chest radiograph and rapid human immunodeficiency virus (HIV) testing (Alere Determine™ HIV-1/2 Ab/Ag; Abbott Laboratories, Chicago, IL, USA), with labora-tory serology confirmation if positive (4 th generation Liaison XL Murex HIV Ab/Ag assay [DiaSorin, Saluggia, Italy]; 6 Hexagon HIV1/2 [HUMAN Diagnostics, Wiesbaden, Germany]; Geenius HIV-1/2 confirmation assay [Bio-Rad, Hercules, CA, USA]) and investigations as clinically indicated (e.g., full blood count, urea and electrolytes, liver function tests, electrocardiogram, echocardiography, pleural aspirate, peak expiratory flow rate, sputum TB culture and/or microbiology). All patients had a minimum of 2-and 4-week follow-ups; the number of follow-up visits was increased according to clinical need.…”

Section: Methodsmentioning

confidence: 99%

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert^® MTB/Rif era

Jayasooriya

Jobe

Badjie

et al. 2019

public health action

View full text Add to dashboard Cite

In some low and middle-income countries, 10–20% of patients presenting with a persistent cough have tuberculosis (TB). Once TB is excluded, health service provision for alternative diagnoses is limited. We prospectively studied patients with two Xpert-negative sputum results presenting to a TB clinic in The Gambia. Of 239 patients, 108 did not have TB; 65/102 (6 were lost to follow-up) had alternative diagnoses, 24.6% of which were non-respiratory; 37/102 had no diagnosis, 27.0% of whom were HIV-1-positive; 37.8% had a history of TB and 24.3% smoked. We highlight the need for general health service integration with TB platforms and exploration of non-TB patients with chronic respiratory symptoms.

show abstract

Section: Methodsmentioning

confidence: 99%

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert^® MTB/Rif era

Jayasooriya

Jobe

Badjie

et al. 2019

public health action

View full text Add to dashboard Cite

show abstract

“…This assay platform has recently been evaluated concerning the assays for HBsAg, anti‐HCV and HIV Ag/Ab (Alonso et al , ; Krawczyk et al , ; Lemee et al , ). In addition, a study on operative performance and efficiency of this assay platform has been conducted elsewhere (Fruttero et al , ).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a new platform has been introduced on the market, the LIAISON® XL chemiluminescence (CLIA) analyser (DiaSorin S.p.A, Vercelli, Italy), with a complete panel of assays for donor screening (Marquette & Blum, ; Alonso et al , ; Krawczyk et al , ; Lemee et al , ).…”

mentioning

confidence: 99%

Performance of Liaison XL automated immunoassay platform for blood‐borne infection screening on hepatitis B, hepatitis C, HIV 1/2, HTLV 1/2 and Treponema pallidum serological markers

Malm

Kragsbjerg

Andersson

2015

Transfusion Medicine

View full text Add to dashboard Cite

show abstract

“…As new immunoassay or chemiluminescence screening tests from companies such as Ortho, Abbott and Bayer come onto the market, the tables of threshold values (such as the S/CO ratio) have been updated using the values for each, but there are no indications concerning the recently available chemiluminescence test of DiaSorin. The performance of this system in detecting infectious disease has been previously tested, but not for this specific purpose. The aim of this study was to determine a threshold value for the DiaSorin LIAISON XL anti‐HCV test above which at least 95% of the samples are positive to an additional antibody test.…”

Section: Introductionmentioning

confidence: 99%

Threshold value of LIAISON XL anti‐HCV screening assay predicting positive immunoblotting results

Paschale

Manco

Arpino

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

Some international guidelines recommend evaluating the need to confirm positive anti-hepatitis C virus (HCV) antibody screening results by means of a more specific antibody or molecular biology test on the basis of a screening threshold value (such as the sample signal/cut-off ratio) that can predict the positivity of additional antibody testing in at least 95% of cases. The aim of this study was to determine the threshold value of the DiaSorin LIAISON XL chemiluminescence test. Two hundred and twenty-eight routine laboratory samples that were chemiluminescence positive for anti-HCV antibodies but had different signal/cut-off ratios were assayed using immunoblotting, which indicated that 155 (68.0%) were positive, 40 (17.5%) were negative, and 33 (14.5%) were indeterminate. When the samples were divided on the basis of their signal/cut-off ratios, 95.5% of the samples with a ratio of ≥3.5 were positive as against 74.1% of the positive or indeterminate samples with a ratio of <3.5. Statistical analysis using Youden's index and a receiver operating characteristic curve showed that the optimum cut-off value was 3.65. These findings indicate that, when using the LIAISON XL system for anti-HCV antibody screening, a signal/cut-off ratio of ≥3.65 makes further confirmatory tests unnecessary.

show abstract

Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

Cited by 8 publications

References 16 publications

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert^® MTB/Rif era

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert^® MTB/Rif era

Performance of Liaison XL automated immunoassay platform for blood‐borne infection screening on hepatitis B, hepatitis C, HIV 1/2, HTLV 1/2 and Treponema pallidum serological markers

Threshold value of LIAISON XL anti‐HCV screening assay predicting positive immunoblotting results

Contact Info

Product

Resources

About

Performance of the Liaison XL Murex HIV Ab/Ag Test on Clinical Samples Representing Current Epidemic HIV Variants

Cited by 8 publications

References 16 publications

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert® MTB/Rif era

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert® MTB/Rif era

Performance of Liaison XL automated immunoassay platform for blood‐borne infection screening on hepatitis B, hepatitis C, HIV 1/2, HTLV 1/2 and Treponema pallidum serological markers

Threshold value of LIAISON XL anti‐HCV screening assay predicting positive immunoblotting results

Contact Info

Product

Resources

About

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert^® MTB/Rif era

The burden of non-TB lung disease presenting to TB clinics in The Gambia: preliminary data in the Xpert^® MTB/Rif era